文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

呼吸同步雾化肺表面活性物质治疗猪急性呼吸窘迫综合征模型

Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.
PubMed 文献 · Crit Care Explor · 2021-02-15
一句话结论在重度ARDS猪模型中,呼吸同步雾化牛肺表面活性物质(名义剂量<30 mg/kg)可使PaO2/FIO2快速恢复至约300,且未见给药相关并发症。

该临床前研究在体外评估了一种新型呼吸同步雾化器的粒径分布与输送剂量,并在重度ARDS(PaO2/FIO2<100)成年猪模型中比较雾化肺表面活性物质(治疗组,n=4)与雾化生理盐水(对照组,n=3)的生理效应。结果:质量中位气溶胶直径为2.8 µm,体外机械通气时输送到气管插管远端的剂量为85%±5%,雾化器可连续工作至20剂、每剂108 mg表面活性物质。治疗组在名义剂量<30 mg/kg下氧合快速改善,PaO2/FIO2接近完全恢复至约300,呼气末肺容积增加;对照组在4.5小时内PaO2/FIO2持续<100且呼气末肺容积降低。治疗组表面活性物质磷脂含量更高、肺部炎症和病理损伤指标更低。作者认为呼吸同步雾化牛肺表面活性物质似乎是COVID-19和其他重度ARDS安全可行的治疗选择。

要点

  • 在重度ARDS(PaO2/FIO2<100)猪模型中,雾化牛肺表面活性物质名义剂量<30 mg/kg使PaO2/FIO2快速恢复至约300,而对照组4.5小时内持续<100。
  • 体外机械通气时,呼吸同步雾化器输送到气管插管远端的剂量为85%±5%,质量中位气溶胶直径为2.8 µm。
  • 雾化器可工作至20剂、每剂108 mg表面活性物质;治疗期间未见给药相关并发症。
  • 治疗组表面活性物质磷脂含量更高、肺部炎症和病理损伤指标更低,但治疗后气道阻力进行性高于对照组,两组通气效应无差异。
  • 作者认为呼吸同步雾化牛肺表面活性物质似乎是COVID-19和其他重度ARDS安全可行的治疗选择。

适用人群与场景

  • 成年猪(体重34.3±0.6 kg),在侵入性机械通气下通过肺灌洗和呼吸机相关肺损伤建立重度ARDS模型(PaO2/FIO2<100)。

诊断标准与关键阈值

  • 重度ARDS模型标准:PaO2/FIO2<100。

处置流程与药物剂量

  • 使用新型呼吸同步雾化器雾化牛肺表面活性物质,治疗组名义剂量<30 mg/kg。
  • 雾化器可工作至20剂、每剂108 mg表面活性物质。

研究设计与关键结果

  • 临床前研究:体外分析雾化器粒径分布和模拟通气下吸入剂量;体内在重度ARDS猪模型比较雾化肺表面活性物质(治疗组,n=4)与雾化生理盐水(对照组,n=3)。
  • 质量中位气溶胶直径为2.8 µm;体外机械通气时输送到气管插管远端的剂量为85%±5%。
  • 治疗组(n=4)在名义剂量<30 mg/kg下氧合快速改善,PaO2/FIO2接近完全恢复至约300,呼气末肺容积增加;对照组(n=3)在4.5小时内PaO2/FIO2持续<100且呼气末肺容积降低。
  • 治疗组表面活性物质磷脂含量高于对照组,肺部炎症和病理肺损伤指标低于对照组。
  • 未见与雾化表面活性物质相关的给药期间并发症;但治疗组治疗后气道阻力进行性高于对照组,两组通气效应无差异。

证据类型、等级与局限

  • 证据类型:临床前研究(体外分析+在体猪模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,呼吸同步雾化牛肺表面活性物质似乎是COVID-19和其他重度ARDS安全可行的治疗选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Effective treatment options for surfactant therapy in acute respiratory distress syndrome and coronavirus disease 2019 have not been established. To conduct preclinical studies in vitro and in vivo to evaluate efficiency, particle size, dosing, safety, and efficacy of inhaled surfactant using a breath-synchronized, nebulized delivery system in an established acute respiratory distress syndrome model.

DESIGN: Preclinical study.

SETTING: Research laboratory.

SUBJECTS: Anesthetized pigs.

INTERVENTION: In vitro analysis included particle size distribution and inhaled dose during simulated ventilation using a novel breath-synchronized nebulizer. Physiologic effects of inhaled aerosolized surfactant (treatment) were compared with aerosolized normal saline (control) in an adult porcine model (weight of 34.3 ± 0.6 kg) of severe acute respiratory distress syndrome (Pao2/Fio2 <100) with lung lavages and ventilator-induced lung injury during invasive ventilation.

MEASUREMENTS AND MAIN RESULTS: Mass median aerosol diameter was 2.8 µm. In vitro dose delivered distal to the endotracheal tube during mechanical ventilation was 85% ± 5%. Nebulizers were functional up to 20 doses of 108 mg of surfactant. Surfactant-treated animals (n = 4) exhibited rapid improvement in oxygenation with nearly full recovery of Pao2/Fio2 (~300) and end-expiratory lung volumes with nominal dose less than 30 mg/kg of surfactant, whereas control subjects (n = 3) maintained Pao2/Fio2 less than 100 over 4.5 hours with reduced end-expiratory lung volume. There was notably greater surfactant phospholipid content and lower indicators of lung inflammation and pathologic lung injury in surfactant-treated pigs than controls. There were no peridosing complications associated with nebulized surfactant, but surfactant-treated animals had progressively higher airway resistance post treatment than controls with no differences in ventilation effects between the two groups.

CONCLUSIONS: Breath-synchronized, nebulized bovine surfactant appears to be a safe and feasible treatment option for use in coronavirus disease 2019 and other severe forms of acute respiratory distress syndrome.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. DiBlasi RM, Kajimoto M, Poli JA, et al. Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome. Crit Care Explor. 2021. PMID: 33604579. doi:10.1097/CCE.0000000000000338

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。